Leerink Partners maintains Viridian Therapeutics at Outperform, raises price target to $54 from $50
Leerink Partners kept its Outperform rating on Viridian Therapeutics and increased its price target to $54 from $50, citing an 85.9% upside from the Nov 4 close of $29.05. Recent analyst targets for the company range from $33 to $42.
How this was made

The 30-second read
Why it matters
The upgrade may trigger short covering and new buying, modestly lifting the share price.
Market read
A price‑target increase is a fresh, material piece of information for VRDN, offering a short‑term trading edge.
What to watch
Potential dilution from future financing rounds not addressed.
Background
Analyst rating actions are a common catalyst for small‑cap biotech stocks.
Ticker impact
Leerink Partners raised its price target on Viridian Therapeutics to $54, indicating a bullish outlook.
upward pressure as investors price in the higher target.
Target increase from $50 to $54 signals confidence in near‑term performance, likely prompting buying interest.
Market effects
May lift sentiment in the biotech/therapeutics sector.
Limited to U.S. biotech investors.
Minimal global impact.
Counterpoint
Target raise could be premature if upcoming trial data disappoints.
Key entities
- Analyst FirmLeerink Partners
Equity research firm that issued the rating upgrade.
- CompanyViridian Therapeutics
Biotech company focused on therapeutic development.
